The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system.

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring ...

Stock futures dipped on Thursday as investors weighed President Trump’s 90-day tariff reprieve for select countries, which ...

What should investors do during a market downturn? Some might resort to panic selling, but that's hardly a good strategy.

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

The San Diego-based medical device company stated that the Dexcom G7 15 Day has an overall Mean Absolute Relative Difference (MARD) of 8.0%, showcasing its precision in glucose level readings. The ...

DexCom, Inc. , the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the ...

DexCom DXCM underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing ...

DexCom Inc. closed 52.68% below its 52-week high of $141.25, which the company reached on April 11th.

Mizuho analyst Anthony Petrone initiated coverage of DexCom (DXCM) with an Outperform rating and $85 price target The firm cites its positive ...

Global drugmakers and MedTech companies bounced back after U.S. President Donald Trump issued a 90-day pause on reciprocal ...

Shares of DexCom Inc. DXCM slipped 1.53% to $60.69 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.57% to 4,982.77 and Dow ...